Healthcare company-building profile
Technology and Innovation Development Office (TIDO)
Boston Children's Hospital
Source-based profile
Program at a Glance
- Program type
- Accelerator
- Program category
- Health system accelerator
- Organization
- Boston Children's Hospital
- Organization type
- Hospital or health system
- Location
- Boston, Massachusetts
- Company stage served
- Research or idea stage
- Cohort or participation model
- Not publicly documented
- Investment or funding offered
- Not publicly documented
- Published investment terms
- Not publicly documented
- Equity or fee model
- Not publicly documented
- Clinical or hospital connection
- Yes
- Application status
- Active
Public description
About the program
TIDO is Boston Children's Hospital's central technology transfer and commercialization office, managing all intellectual property arising from the hospital's clinical and research enterprise. It guides faculty inventors through disclosure, patenting, and licensing, negotiates license and sponsored research agreements, and establishes research and development partnerships with life science companies. TIDO runs the Therapeutic and Medical Device Accelerator (launched April 2024, with inaugural awards announced May 2025) and a Technology Development Fund that provide non-dilutive capital and project management to de-risk early pediatric assets toward licensing or company formation. A companion Innovation and Digital Health Accelerator (IDHA) builds and commercializes digital health and AI products developed inside the hospital. Outside companies engage through industry-sponsored research, option and license agreements, co-development partnerships, and startup formation around hospital IP.
What the program publicly emphasizes
Focus areas and features
- Category: Health system accelerator
Publicly documented people and network
Program leadership and alumni
- Program leader
- Irene Abrams — Vice President, Technology Development and New Ventures (head of TIDO)
- Notable alumni named in public materials
- Spinouts and licensed companies include Orchard Therapeutics (gene therapy for rare disorders); Morphic Therapeutic (oral integrin therapeutics); Emulate, Inc. (Organs-on-Chips); Affinivax (vaccine platform); Etiometry (ICU predictive analytics); Circulation (patient transportation platform serving more than 1,000 health facilities nationally); Rebion (pediatric vision screening); InVivo Therapeutics (spinal cord injury biopolymers); Licensed products include Vonvendi (recombinant von Willebrand factor), the EZ Board medical communication system, the iSpawn zebrafish breeding tank, and a dystrophin muscular dystrophy diagnostic; Therapeutic and Medical Device Accelerator launched April 2024 with inaugural project awards announced May 2025; Aggregate licensing revenue figures are not published
Sources
External source links open in a new tab.